Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder

Clicks: 217
ID: 112180
2020
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Growing evidence supports the treatment of MDD through modulation of dysregulated glutamate neurotransmission. This study assessed the putative antidepressant and precognitive effects of decoglurant, a metabotropic glutamate receptor type 2/3 antagonist.
Reference Key
umbricht2020therandomized, Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Daniel Umbricht;Markus Niggli;Patricia Sanwald-Ducray;Dennis Deptula;Rema Moore;Waltraud Grünbauer;Lauren Boak;Paulo Fontoura;
Journal the journal of clinical psychiatry
Year 2020
DOI DOI not found
URL
http://www.psychiatrist.com/JCP/article/Pages/2020/v81/18m12470.aspx
Keywords
keywords:antidepressants; keywords:cognition; keywords:depression; original research; jcp; j clin psychiatry:nlm:journal article; j clin psychiatry:portico:research-article

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.